Amivantamab/hyaluronidase

Amivantamab/hyaluronidase, sold under the brand name Rybrevant Faspro, is a fixed-dose combination medication used for the treatment of non-small cell lung cancer. It contains amivantamab, a bispecific epidermal growth factor receptor (EGFR)-directed and hepatocyte growth factor receptor (MET)-directed antibody; and hyaluronidase, an endoglycosidase. It is given by subcutaneous infusion.